πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

ALMIRALL S.P.A Patents

Full USPTO pharma patent portfolio for ALMIRALL S.P.A β€” grant dates, expiration, and drug cross-links.

Patents
308
Expiring ≀24m
14

Quick answer

ALMIRALL S.P.A has 308 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 14 expire within 24 months β€” use filters for patent-cliff planning.

Page 4 of 7

  1. US 9409972

    Pharmaceutical composition and method of preparing same

    Expires Mon Aug 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9388189

    Pyrrolotriazinone derivatives as PI3K inhibitors

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9388408

    Oligonucleotide-based inhibitors comprising locked nucleic acid motif

    Expires Mon Jul 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9376681

    miR-29 mimics and uses thereof

    Expires Mon Jun 23 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9345780

    Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9346759

    Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the Ξ²2 adrenergic receptor

    Expires Mon May 19 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9340547

    Pyrrolotriazinone derivatives as inhibitors P13K

    Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9333195

    Quinuclidine derivatives and medicinal compositions containing the same

    Expires Mon May 05 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9315463

    Cyclohexylamine derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist activities

    Expires Mon Apr 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9302013

    Active principle for mitigating undesired medical conditions

    Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9272990

    Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis

    Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9260416

    Heterocyclic autotaxin inhibitors and uses thereof

    Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9259414

    Glycopyrrolate salts

    Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9254262

    Dosage and formulation

    Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9238676

    Peptide and peptidomimetic inhibitors

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9233108

    Cyclohexylamine derivatives having Ξ²2 adrenergic agonist and M3 muscarinic antagonist activities

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9220683

    Lipids and compositions for the delivery of therapeutics

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9206183

    Substituted pyrazolo[1,5-a]pyridines as JAK inhibitors

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9186325

    Lipids and compositions for the delivery of therapeutics

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9163235

    Inhibitors of the miR-15 family of micro-RNAs

    Expires Mon Oct 15 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9139554

    Amino lipids and methods for the delivery of nucleic acids

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9132201

    Hydrogels based on polymers of dextran tyramine and tyramine conjugates of natural polymers

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9133200

    Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as JAK inhibitors

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9108918

    Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate

    Expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9090573

    Compounds as lysophosphatidic acid receptor antagonists

    Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9056100

    Quinuclidine derivatives and medicinal compositions containing the same

    Expires Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9051567

    Methods for increasing efficacy of lipid formulated siRNA

    Expires Mon Jun 04 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9034311

    Pyridin-2(1 H)-one derivatives as JAK inhibitors

    Expires Mon May 14 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9012225

    Lipophilic polynucleotide conjugates

    Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9006462

    Glycopyrrolate salts

    Expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 8999351

    Lipids and compositions for the delivery of therapeutics

    Expires Mon Apr 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9000025

    Autotaxin inhibitors and uses thereof

    Expires Mon Apr 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 8946271

    Water soluble furoxan derivatives having antitumor activity

    Expires Mon Jan 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 8883202

    Lipid compositions

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 8884034

    TOFA analogs useful in treating dermatological disorders or conditions

    Expires Mon Nov 06 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 8865728

    Combinations comprising methotrexate and DHODH inhibitors

    Expires Mon Oct 16 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 8841295

    5-lipoxygenase-activating protein (FLAP) inhibitors

    Expires Mon Sep 18 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 8815917

    DP2 antagonist and uses thereof

    Expires Mon Aug 21 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 8802699

    Quinuclidine derivatives and medicinal compositions containing the same

    Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 8802644

    Lipid formulation

    Expires Mon Aug 07 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 8785393

    Ophthalmic pharmaceutical compositions of DP2 receptor antagonists

    Expires Mon Jul 17 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 8778983

    Polycyclic compounds as lysophosphatidic acid receptor antagonists

    Expires Mon Jul 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 8772288

    Substituted spiro[cycloalkyl-1,3β€²-indo]-2β€²(1β€²H)-one derivatives and their use as P38 mitogen-activated kinase inhibitors

    Expires Mon Jul 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 8772495

    5-lipoxygenase-activating protein inhibitor

    Expires Mon Jul 03 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 8754233

    Pyrazolylbenzothiazole derivatives and their use as therapeutic agents

    Expires Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 8747919

    Pharmaceutical composition and method of preparing same

    Expires Mon Jun 05 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 8722082

    Lipids and compositions for the delivery of therapeutics

    Expires Mon May 08 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 8710081

    5-lipoxygenase-activating protein (FLAP) inhibitors

    Expires Mon Apr 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does ALMIRALL S.P.A have?

308 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do ALMIRALL S.P.A patents expire?

14 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.